Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight

globenewswire.com
JNJ Johnson & Johnson's drug Amivantamab (RYBREVANT) is mentioned as an emerging therapy expected to drive growth in the head and neck squamous cell carcinoma market. BNTX BioNTech's drug BNT113 is identified as an emerging therapy expected to contribute to the growth of the head and neck squamous cell carcinoma market. CUE Cue Biopharma's drug CUE-101 is listed as an emerging therapy that will propel the growth of the head and neck squamous cell carcinoma market. GMAB Genmab's Petosemtamab is highlighted with positive developments, including Breakthrough Therapy Designation from the FDA for recurrent/metastatic HNSCC, indicating strong potential for market growth. IMPP Immutep's Eftilagimod alpha (Efti) has received Fast Track designation from the FDA for first-line HNSCC, suggesting strong potential and market impact. INO Inovio Pharmaceuticals is mentioned as a company with a drug (INO-3112) in development for head and neck squamous cell carcinoma, but no specific sentiment or strength is detailed. AZN AstraZeneca is listed as a company involved in recurrent head and neck squamous cell carcinoma pipeline, but no specific drug or sentiment is detailed. GSK GlaxoSmithKline is mentioned in the context of recurrent HNSCC pipeline and HPV16+ cancers, but no specific drug or sentiment is detailed. MRK Merck is mentioned in relation to recurrent HNSCC pipeline, HPV16+ HNSCC market, and HPV16+ cancers market, but no specific drug or sentiment is detailed. BMY Bristol Myers Squibb is listed as a company in the HPV16+ Head and Neck Squamous Cell Carcinoma Market, but no specific drug or sentiment is detailed. EXEL Exelixis is listed as a company in the HPV16+ Head and Neck Squamous Cell Carcinoma Market, but no specific drug or sentiment is detailed. REGN Regeneron Pharmaceuticals is mentioned in the context of HPV16+ HNSCC market and HPV16+ cancers market, but no specific drug or sentiment is detailed. PDSB PDS Biotechnology is mentioned in relation to HPV16+ HNSCC market, HPV16+ cancers market, and HPV16+ cancers clinical trials, but no specific drug or sentiment is detailed. IOVA Iovance Biotherapeutics is mentioned as a company in the HPV16+ Head and Neck Squamous Cell Carcinoma Market, but no specific drug or sentiment is detailed. RPTX RAPT Therapeutics is listed as a company in the HPV16+ Head and Neck Squamous Cell Carcinoma Market, but no specific drug or sentiment is detailed.

Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight New York, USA, July 13, 2026 (GLOBE NEWSWIRE) -- Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight

The head and neck squamous cell carcinoma market is experiencing significant growth, driven by the rising incidence of head and neck cancers worldwide, increasing adoption of immunotherapies, targeted therapies, and combination treatment approaches. Additionally, the expected launch of emerging therapies such as Amivantamab (RYBREVANT) (Johnson & Johnson), BNT113 (BioNTech), CUE-101 (Cue Biopharma), Petosemtamab (MCLA-158) (Genmab), Eftilagimod Alfa (Immutep), and others will further propel the market growth.

Recently published Head and Neck Squamous Cell Carcinoma Market Insights report includes a comprehensive understanding of current treatment practices, head and neck squamous cell carcinoma emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Head and Neck Squamous Cell Carcinoma Market Summary

Discover head and neck squamous cell carcinoma market growth opportunities @ https://www.delveinsight.com/report-store/head-and-neck-squamous-cell-carcinoma-market

Key Factors Driving the Growth of the Head and Neck Squamous Cell Carcinoma Market

Aparna Thakur, project manager of forecasting at DelveInsight, said that the growing integration of immune checkpoint inhibitors and novel combinations, such as pembrolizumab with HPV-targeted vaccines, underscores a key advancement in HNSCC management.

Head and Neck Squamous Cell Carcinoma Market Analysis

Learn more about disease-modifying therapies for HNSCC @ Head and Neck Squamous Cell Carcinoma Treatment Market

Head and Neck Squamous Cell Carcinoma Competitive Landscape

Some of the HNSCC drugs under development include Amivantamab (RYBREVANT) (Johnson & Johnson), BNT113 (BioNTech), CUE-101 (Cue Biopharma), Petosemtamab (MCLA-158) (Genmab), Eftilagimod Alfa (Immutep), ISA101 (ISA Pharmaceuticals), Versamune HPV (PDS Biotechnology), abipapogene suvaplasmid (Nykode Therapeutics), INO-3112 (Inovio Pharmaceuticals), and others.

Genmab’s Petosemtamab is a low-fucose, full-length human IgG1 bispecific antibody developed using the BICLONICS platform, targeting both EGFR and Leucine-rich Repeat-containing G-protein-coupled Receptor 5 (LGR5). The therapy is engineered to exert antitumor activity through three distinct mechanisms: suppression of EGFR-mediated signaling pathways, induction of EGFR internalization and degradation following LGR5 engagement in tumor cells, and enhancement of immune-mediated tumor cell elimination via antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).

Petosemtamab is currently being evaluated in the expansion phase of an open-label, multicenter Phase I/II study involving patients with advanced solid tumors, including previously treated recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). An updated clinical data readout is anticipated in 2025. Additionally, the therapy has received Breakthrough Therapy Designation (BTD) from the FDA for second-line recurrent/metastatic HNSCC. Continued development of petosemtamab will require significant additional financial investment.

Immutep’s Eftilagimod alpha (Efti) is a soluble LAG-3 protein that functions as an MHC Class II agonist, designed to activate both innate and adaptive immune responses against cancer. As the first antigen-presenting cell (APC) activator in its class, Efti binds to MHC Class II molecules on APCs, triggering the activation and expansion of key immune cell populations, including CD8+ cytotoxic T cells, CD4+ helper T cells, dendritic cells, natural killer (NK) cells, and monocytes. The therapy also promotes the production of immune-stimulatory cytokines and chemokines, such as IFN-γ and CXCL10, further enhancing antitumor immunity. Efti has been granted Fast Track designation by the FDA for the treatment of first-line HNSCC.

The anticipated launch of these emerging HNSCC therapies are poised to transform the HNSCC market landscape in the coming years. As these cutting-edge HNSCC therapies continue to mature and gain regulatory approval, they are expected to reshape the HNSCC market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

To know more about emerging head and neck squamous cell carcinoma therapies, visit @ Head and Neck Squamous Cell Carcinoma Medication

Recent Developments in the Head and Neck Squamous Cell Carcinoma Market

What is Head and Neck Squamous Cell Carcinoma?

Head and neck squamous cell carcinoma (HNSCC) is the most common type of head and neck cancer, accounting for nearly 90% of malignancies arising in the oral cavity, oropharynx, hypopharynx, and larynx. It develops from the squamous epithelial cells lining the mucosal surfaces of the upper aerodigestive tract. Major risk factors include tobacco use, excessive alcohol consumption, and infection with human papillomavirus (HPV), particularly in oropharyngeal cancers. HNSCC is a heterogeneous disease characterized by varying molecular profiles, clinical presentations, and treatment responses. Management typically involves a multidisciplinary approach incorporating surgery, radiation therapy, chemotherapy, targeted therapies, and immunotherapies, depending on the stage and location of the tumor.

Head and Neck Squamous Cell Carcinoma Epidemiology Segmentation

The head and neck squamous cell carcinoma epidemiology section provides insights into the historical and current HNSCC patient pool and forecasted trends for the leading markets. It has been observed that among EU4 and the UK, site-specific cases of HNSCC were found maximum in the oral cavity in 2025.

The head and neck squamous cell carcinoma market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets segmented into:

Download the report to understand the future of HNSCC treatment @ Head and Neck Squamous Cell Carcinoma Treatment Options

Scope of the Head and Neck Squamous Cell Carcinoma Market Report

Discover more about next-generation HNSCC drugs @ Head and Neck Squamous Cell Carcinoma Clinical Trials

Table of Contents

Related Reports

Recurrent Head and Neck Squamous Cell Carcinoma Clinical Trial Analysis

Recurrent Head and Neck Squamous Cell Carcinoma Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key recurrent HNSCC companies, including AstraZeneca, Astellas, GlaxoSmithKline, Boehringer Ingelheim, Merck, and others.

HPV16+ Head and Neck Squamous Cell Carcinoma Market

HPV16+ Head and Neck Squamous Cell Carcinoma Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key HPV16+ HNSCC companies including Bristol Myers Squibb, Merck, Merus, Exelixis, ISA Pharmaceuticals, Regeneron Pharmaceuticals, PDS Biotechnology, BioNTech, Cue Biopharma, Immutep, Iovance Biotherapeutics, Inovio Pharmaceuticals, MedImmune, Nykode Therapeutics, RAPT Therapeutics, and others.

HPV16+ Cancers Market

HPV16+ Cancers Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key HPV16+ cancers companies, including GlaxoSmithKline, PDS Biotechnology, Merck, Cue Biopharma, ISA Pharmaceuticals, Regeneron Pharmaceuticals, Vaccibody AS, Transgene, Innovio Pharma, Hookipa Pharma, Roche Pharma AG, Invectys, BioNTech, Advaxis, Inc., Precigen, and others.

HPV16+ Cancers Clinical Trial Analysis

HPV16+ Cancers Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key HPV16+ cancers companies, including ISA Pharmaceuticals, Cue Biopharma, Genexine, Vaccibody AS, PDS Biotechnology, BlueSky Immunotherapies GmbH, and others.

Human Papillomavirus Market

Human Papillomavirus Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key HPV companies, including Inovio Pharmaceuticals, ISA Pharmaceuticals, Regeneron Pharmaceuticals, Merck, Pattern Pharma, Nykode, Vaccibody A/S, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.